<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Alvimopan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06274</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Alvimopan is a peripherally acting &#956; opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06274/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06274/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06274.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06274.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06274.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06274.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06274.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06274">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>ADL 8-2698</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Entereg</td><td>Cubist Pharmaceuticals</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>170098-38-1</td></tr><tr><th>Weight</th><td>Average: 424.5326<br>Monoisotopic: 424.236207522</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>32</sub>N<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>UPNUIXSCZBYVBB-JVFUWBCBSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanamido]acetic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">C[C@H]1CN(C[C@H](CC2=CC=CC=C2)C(=O)NCC(O)=O)CC[C@@]1(C)C1=CC(O)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>N-acyl-alpha Amino Acids</td></tr><tr><th>Alternative parents</th><td>Phenylpiperidines; Beta Amino Acids and Derivatives; Phenylpropylamines; Phenols and Derivatives; Polyols; Secondary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Enolates; Carboxylic Acids; Enols</td></tr><tr><th>Substituents</th><td>beta amino acid or derivative; phenylpropylamine; phenol derivative; piperidine; benzene; secondary carboxylic acid amide; carboxamide group; polyol; tertiary amine; enolate; polyamine; carboxylic acid; enol; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at his terminal nitrogen atom.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. Also investigated for use in the treatment of pain (acute or chronic).</td></tr><tr><th>Pharmacodynamics</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Mechanism of action</th><td>Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract. Unlike methylnaltrexone (another peripherally acting mu-receptor antagonist) that bears a quaternary amine, alvimopan owes its selectivity for peripheral receptors to its kinetics. Alvimopan binds to peripheral mu-receptors with a Ki of 0.2 ng/mL and dissociates slower than most other ligands.</td></tr><tr><th>Absorption</th><td>Alvimopan's high affinity for the peripheral mu-receptor results in an absolute oral bioavailability of less than 7%.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>30&#177;10 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>80% to 90% of systemically available alvimopan is bound to plasma protein.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Alvimopan undergoes no significant hepatic metabolism, but is metabolized by intestinal flora. Gut metabolism produces an active metabolite with no clinically significant contribution to drug effect.</p></td></tr><tr><th>Route of elimination</th><td>Biliary secretion was considered the primary pathway for alvimopan elimination.  Unabsorbed drug and unchanged alvimopan resulting from biliary excretion were then hydrolyzed to its &#8216;metabolite&#8217; by gut microflora. Feces (via biliary excretion) &amp; urine (35%)</td></tr><tr><th>Half life</th><td>10 to 17 hours (gut metabolite: 10 to 18 hours) </td></tr><tr><th>Clearance</th><td><ul>
	<li>402 &#177; 89 mL/min</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9103</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.96</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6875</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8627</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6845</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6478</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8596</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7966</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7292</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5908</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9362</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9109</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7964</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8729</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8447</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9803</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8684
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8594
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9694
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6978 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9599
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7208
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Adolor corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.adolor.com">Adolor Corp.</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.pharm-int.com">Pharmaceutics International Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule, coated</td><td>Oral</td><td>12mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00802">Alfentanil</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB00921">Buprenorphine</a></td><td>Opioids like buprenorphine may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. Consider therapy modification.</td></tr><tr><td><a href="/drugs/DB00611">Butorphanol</a></td><td>Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB00257">Clotrimazole</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB00318">Codeine</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01529">Dextromoramide</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00647">Dextropropoxyphene</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01209">Dezocine</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01501">Difenoxin</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01551">Dihydrocodeine</a></td><td>Opioids may enhance Alvimopan toxicity, especially when opiate use for more than 7 days is in place prior to alvimopan initiation. Alvimopan is contraindicated for use if patients have been dosed with opioids for more than 7 consecutive days. </td></tr><tr><td><a href="/drugs/DB01081">Diphenoxylate</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01491">Dipipanone</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00813">Fentanyl</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01452">Heroin</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00956">Hydrocodone</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00327">Hydromorphone</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB01227">Levomethadyl Acetate</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00854">Levorphanol</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00295">Morphine</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00844">Nalbuphine</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00497">Oxycodone</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01192">Oxymorphone</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB01113">Papaverine</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00652">Pentazocine</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00454">Pethidine</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB00708">Sufentanil</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB06204">Tapentadol</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>